secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0000950170-23-029354
Event type: regulatory
Sentiment:  positive
Materiality: 1.00
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants accelerated approval for Sarepta's ELEVIDYS gene therapy for Duchenne MD
--------------------------------------------------------------------------------

- First FDA-approved gene therapy for Duchenne muscular dystrophy; for ambulatory patients aged 4-5.
- Accelerated approval based on micro-dystrophin expression; confirmatory trial EMBARK reads out late 2023.
- Contraindicated in patients with deletions in exon 8 and/or 9 of the DMD gene.
- Common adverse reactions include vomiting, nausea, liver enzyme increases, pyrexia, thrombocytopenia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000095017023029354/0000950170-23-029354-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000095017023029354/srpt-20230622.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-029354

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer